Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Nov;142(5):493-500.
doi: 10.1111/ane.13293. Epub 2020 Jul 6.

Dexmedetomidine for EEG sedation in children with behavioral disorders

Francesca Sfriso  1 , Claudia Maria Bonardi  1 , Francesco Viaggi  1 , Stefano Sartori  2 , Clementina Boniver  2 , Francesco Martinolli  3 , Liviana Da Dalt  3 , Anna Chiara Frigo  4 , Alessandro Mazza  3 , Angela Amigoni  5
Affiliations
Clinical Trial

Dexmedetomidine for EEG sedation in children with behavioral disorders

Francesca Sfriso et al. Acta Neurol Scand. 2020 Nov.

Abstract

Objective: To evaluate the efficacy and safety of sedation with dexmedetomidine, a highly selective α2-agonist with sedative effect, for EEG recording in children with behavioral disorders.

Material and methods: Prospective observational study on children with behavioral disorders undergoing EEG at the Pediatric Hospital in Padova, Italy. A 2 mcg/kg intravenous bolus of dexmedetomidine was administered, followed by a 1-2 mcg/kg/h infusion. If necessary, bolus was repeated up to 3 times to reach the target level of sedation, assessed by Pediatric Sedation State Scale. Patients were fully monitored before, during and after the procedure until complete recovery. EEG recording quality, and caregivers' satisfaction were collected. Any adverse effect was registered using SIVA score.

Results: For this preliminary study, 19 patients were enrolled. EEG was successfully completed in all of them. Mean total dose of dexmedetomidine was 3.7 ± 1.7 mcg/kg. Adequate sedation was achieved within 11.9 ± 8 minutes. Mean time to first awakening was 30.9 ± 36.9 minutes and time to complete recovery 113.3 ± 92.7 minutes. Adverse effects (hypotension, bradycardia) were reported in 10 patients, all classified as "minor." EEG recording quality was good or excellent. Parents' satisfaction was high in all the interviewed families.

Conclusions: Intravenous dexmedetomidine as a single drug showed an excellent efficacy and good safety profile for EEG recording in children with behavioral disorders.

Keywords: EEG; epilepsy; pediatric neurology; sedation.

PubMed Disclaimer

References

REFERENCES

    1. Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol. 2002;1(6):352-358.
    1. Besag FM. Epilepsy in patients with autism: links, risks and treatment challenges. Neuropsychiatr Dis Treat. 2017;18(14):1-10.
    1. Ebrahim ZY, Schubert A, Van Ness P, Wolgamuth B, Awad I. The effect of propofol on the electroencephalogram of patients with epilepsy. Anesth Analg. 1994;78(2):275-279.
    1. Meyer S, Shamdeen MG, Kegel B, et al. Effect of propofol on seizure-like phenomena and electroencephalographic activity in children with epilepsy vs children with learning difficulties. Anaesthesia. 2006;61(11):1040-1047.
    1. Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893-913.

LinkOut - more resources